Search

Pfizer opens access to portfolio for low-income countries - BioPharma-Reporter.com

singkrata.blogspot.com

The action, which Pfizer titles ‘An Accord for a Healthier World’, will begin with five countries, Rwanda, Ghana, Malawi, Senegal, and Uganda.

According to the company, the lessons learned in these countries will then inform the roll out to the further 40 lower-income and lower-middle income countries that will make up the complete accord.

Pfizer will work with healthcare officials in the five countries to determine how best to support diagnosis, healthcare professional education and training, as well as supply chain management and infrastructure enhancements.

In total, this will see Pfizer provide 23 medicines and vaccines on a not-for-profit basis, while the company also pledges to provide future patented medicines and vaccines in the same fashion.

The portfolio of medicines made available treat infectious diseases, certain cancers, as well as rare and inflammatory diseases. The company projects that making the treatments available to the 45 countries could potentially save one million individuals, and support the better health of half a million living with chronic disease.

Further work

At the same time as announcing the accord, Pfizer revealed that it would also work to advance the development of vaccines candidates for the prevention of group B streptococcus, with the Bill & Melinda Gates Foundation provided funding to the project. There are also plans to progress a vaccine against respiratory syncytial virus.

Both Pfizer and the Gates Foundation called upon other ‘health leaders and organizations’ to join the Accord to tackle the global health equity gap.

Adblock test (Why?)



"low" - Google News
May 30, 2022 at 03:40PM
https://ift.tt/o1hgDCZ

Pfizer opens access to portfolio for low-income countries - BioPharma-Reporter.com
"low" - Google News
https://ift.tt/aewGs6b


Bagikan Berita Ini

0 Response to "Pfizer opens access to portfolio for low-income countries - BioPharma-Reporter.com"

Post a Comment

Powered by Blogger.